Table 1 Summary of animal information
Animal | DOB (year.month.day) | Sex | Dose (mg/kg) | Dose time (GD) | Birth condition | Experimental analysis | Behavioral tests |
|---|---|---|---|---|---|---|---|
Con 1 | 2020.09.18 | Male | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 2 | 2020.09.18 | Male | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 3 | 2020.09.18 | Male | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 4# | 2020.09.18 | Male | NT | 50, 54 | Full term; deceased on 2020.11.09 | Gross anatomy analysis | None |
Con 5 | 2020.09.18 | Male | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 6 | 2020.09.18 | Female | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 7 | 2020.09.18 | Male | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 8 | 2020.09.18 | Female | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 9 | 2020.09.18 | Female | NT | 50, 54 | Full term | Gross anatomy analysis | None |
Con 10 | 2020.09.18 | NA | NT | 50, 54 | Stillbirth (GD 112) | Gross anatomy analysis | None |
Con 11 | 2020.09.18 | NA | NT | 50, 54 | Stillbirth (GD 112) | Gross anatomy analysis | None |
Con 12 | 2020.09.18 | NA | NT | 50, 54 | Stillbirth (GD 112) | Gross anatomy analysis | None |
VPAM200 1# | 2020.09.22 | Female | 200 | 50, 54 | Full term; deceased on 2020.09.24 | Gross anatomy analysis | None |
VPAM200 2# | 2020.09.22 | Female | 200 | 50, 54 | Full term; deceased on 2020.09.24 | Gross anatomy analysis | None |
VPAM200 3# | 2020.09.22 | Male | 200 | 50, 54 | Full term; deceased on 2020.09.24 | Gross anatomy analysis | None |
VPAM200 4# | 2020.09.22 | Female | 200 | 50, 54 | Full term; deceased on 2020.09.24 | Gross anatomy analysis | None |
VPAM200 5# | 2020.09.22 | NA | 200 | 50, 54 | Stillbirth (GD 112) | Gross anatomy analysis | None |
VPAM200 6# | 2020.09.22 | NA | 200 | 50, 54 | Stillbirth (GD 112) | Gross anatomy analysis | None |
VPAM200 7# | 2020.09.22 | NA | 200 | 50, 54 | Stillbirth (GD 112) | Gross anatomy analysis | None |
Con 13 | 2020.11.06 | Male | NT | NT | Full term | Behavioral and molecular assays | Test set 1 |
Con 14 | 2020.11.06 | Male | NT | NT | Full term | Behavioral assay | Test set 1 |
Con 15 | 2020.11.06 | Male | NT | NT | Full term | Behavioral assay | Test set 1 |
Con 16# | 2020.11.06 | Male | NT | NT | Full term; deceased on 2021.01.05 | Behavioral assay | Test set 1 |
Con 17 | 2020.11.06 | Male | NT | NT | Full term | Behavioral and molecular assays | Test set 1 |
Con 18 | 2020.11.07 | Female | NT | NT | Full term | Behavioral and molecular assays | Test set 1 |
Con 19 | 2020.11.07 | Female | NT | NT | Full term | Behavioral assay | Test set 1 |
Con 20 | 2020.11.07 | Female | NT | NT | Full term | Behavioral assay | Test set 1 |
Con 21 | 2020.11.07 | Female | NT | NT | Full term | Behavioral assay | Test set 1 |
VPAM50 8 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral and molecular assays | Test set 1 |
VPAM50 9 | 2020.12.15 | Female | 50 | 50, 54 | Full term | Behavioral and molecular assays | Test set 1 |
VPAM50 10 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral and molecular assays | Test set 1 |
VPAM50 11 | 2020.12.15 | Female | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 12 | 2020.12.15 | Female | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 13 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 14 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 15 | 2020.12.15 | Female | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 16 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 17 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 18 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPAM50 19 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
VPA M50 20 | 2020.12.15 | Male | 50 | 50, 54 | Full term | Behavioral assay | Test set 1 |
Con 23 | 2021.08.29 | Male | NT | NT | Full term | Behavioral assay, Golgi staining and RNA-seq | Test set 2 |
Con 24 | 2021.08.29 | Male | NT | NT | Full term | Behavioral assay, Golgi staining and RNA-seq | Test set 2 |
Con 25 | 2021.08.29 | Female | NT | NT | Full term | Behavioral assay and brain morphology | Test set 2 |
Con 26 | 2021.08.29 | Male | NT | NT | Full term | Behavioral assay, Golgi staining and RNA-seq | Test set 2 |
Con 27 | 2021.08.29 | Male | NT | NT | Full term | Behavioral assay and brain morphology | Test set 2 |
Con 28 | 2021.08.29 | Female | NT | NT | Full term | Behavioral assay | Test set 2 |
Con 29 | 2021.08.29 | Male | NT | NT | Full term | Behavioral assay | Test set 2 |
Con 30 | 2021.08.29 | Male | NT | NT | Full term | Behavioral assay and brain morphology | Test set 2 |
VPAE75 21 | 2021.09.03 | Male | 75 | 16, 20 | Stillbirth (GD 114) | Gross anatomy analysis | Test set 2 |
VPAE75 22 | 2021.09.03 | Male | 75 | 16, 20 | Stillbirth (GD 114) | Gross anatomy analysis | Test set 2 |
VPAE75 23 | 2021.09.03 | Male | 75 | 16, 20 | Stillbirth (GD 114) | Gross anatomy analysis | Test set 2 |
VPAE75 24 | 2021.09.03 | Male | 75 | 16, 20 | Stillbirth (GD 114) | Gross anatomy analysis | Test set 2 |
VPAE75 25 | 2021.09.03 | Male | 75 | 16, 20 | Stillbirth (GD 114) | Gross anatomy analysis | Test set 2 |
VPAE75 26 | 2021.09.03 | Female | 75 | 16, 20 | Stillbirth (GD 114) | Gross anatomy analysis | Test set 2 |
VPAE75 27 | 2021.09.03 | Female | 75 | 16, 20 | Stillbirth (GD 114) | Gross anatomy analysis | Test set 2 |
VPAE75 28 | 2021.09.03 | Male | 75 | 16, 20 | Full term | Behavioral assay, Golgi staining and RNA-seq | Test set 2 |
VPAE75 29 | 2021.09.03 | Male | 75 | 16, 20 | Full term | Behavioral assay, Golgi staining and RNA-seq | Test set 2 |
VPAE75 30 | 2021.09.03 | Female | 75 | 16, 20 | Full term | Behavioral assay and brain morphology | Test set 2 |
VPAE75 31 | 2021.09.03 | Male | 75 | 16, 20 | Full term | Behavioral assay, Golgi staining and RNA-seq | Test set 2 |
VPAE75 32 | 2021.09.03 | Male | 75 | 16, 20 | Full term | Behavioral assay and brain morphology | Test set 2 |
VPAE75 33 | 2021.09.03 | Female | 75 | 16, 20 | Full term | Behavioral assay and brain morphology | Test set 2 |
